Braidwell
Latest statistics and disclosures from Braidwell's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CAI, Guardant Health, EWTX, Repligen Corp, NBIX, and represent 23.98% of Braidwell's stock portfolio.
- Added to shares of these 10 stocks: KOD (+$58M), CNTA (+$55M), BTSG (+$45M), NRIX (+$41M), ILMN (+$35M), CLDX (+$34M), NEO (+$34M), FULC (+$32M), MBX (+$32M), RAPT (+$32M).
- Started 20 new stock positions in MBX, CNTA, KOD, KPTI, BLLN, XFOR, NTRA, VTYX, ILMN, EOLS. GRAL, NRIX, ICLR, BIIB, BTSG, RAPT, GLUE, RLMD, TERN, CMPX.
- Reduced shares in these 10 stocks: Guardant Health (-$210M), Novocure (-$210M), XENE (-$80M), KRYS (-$79M), APGE (-$65M), CGON (-$59M), DHR (-$44M), ORKA (-$39M), ARGX (-$38M), Karyopharm Therapeutics (-$35M).
- Sold out of its positions in AKRO, ATEC, AMLX, RNA, DAWN, Dexcom, EHC, EXAS, GMED, HTFL. Immunocore Hldgs, Karyopharm Therapeutics, Novocure, REPL, SRPT, SION, THC, RARE, VKTX, RPRX.
- Braidwell was a net seller of stock by $-758M.
- Braidwell has $3.1B in assets under management (AUM), dropping by -7.22%.
- Central Index Key (CIK): 0001920938
Tip: Access up to 7 years of quarterly data
Positions held by Braidwell consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Braidwell
Braidwell holds 73 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Caris Life Sciences (CAI) | 6.7 | $211M | +6% | 7.8M | 26.98 |
|
| Guardant Health Debt 1.250% 2/1 (Principal) | 6.2 | $192M | -52% | 105M | 1.83 |
|
| Edgewise Therapeutics (EWTX) | 4.1 | $129M | 5.2M | 24.82 |
|
|
| Repligen Corp Note 1.000%12/1 (Principal) | 3.5 | $111M | 101M | 1.10 |
|
|
| Neurocrine Biosciences (NBIX) | 3.4 | $107M | -14% | 752k | 141.83 |
|
| Glaukos (GKOS) | 3.3 | $104M | +18% | 922k | 112.91 |
|
| Neogenomics Note 0.250% 1/1 (Principal) | 2.9 | $90M | 100M | 0.89 |
|
|
| Nuvalent Inc-a (NUVL) | 2.6 | $83M | -18% | 821k | 100.59 |
|
| Xenon Pharmaceuticals (XENE) | 2.6 | $82M | -49% | 1.8M | 44.82 |
|
| Cg Oncology (CGON) | 2.5 | $78M | -43% | 1.9M | 41.52 |
|
| Irhythm Technologies Note 1.500% 9/0 (Principal) | 2.3 | $73M | -16% | 52M | 1.40 |
|
| Hinge Health Cl A (HNGE) | 1.9 | $61M | +43% | 1.3M | 46.45 |
|
| Align Technology (ALGN) | 1.9 | $60M | -7% | 381k | 156.15 |
|
| Kodiak Sciences (KOD) | 1.9 | $58M | NEW | 2.1M | 27.96 |
|
| Soleno Therapeutics (SLNO) | 1.8 | $55M | -7% | 1.2M | 46.30 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.8 | $55M | NEW | 2.2M | 25.01 |
|
| Neogenomics Com New (NEO) | 1.7 | $55M | +161% | 4.6M | 11.76 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.7 | $54M | -14% | 2.0M | 26.71 |
|
| Spyre Therapeutics Com New (SYRE) | 1.7 | $54M | -36% | 1.6M | 32.76 |
|
| Dianthus Therapeutics (DNTH) | 1.7 | $53M | +52% | 1.3M | 41.21 |
|
| Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal) | 1.6 | $51M | -34% | 53M | 0.94 |
|
| Celldex Therapeutics Com New (CLDX) | 1.6 | $51M | +214% | 1.9M | 27.16 |
|
| Inspire Med Sys (INSP) | 1.6 | $50M | -38% | 541k | 92.23 |
|
| Krystal Biotech (KRYS) | 1.6 | $50M | -61% | 202k | 246.54 |
|
| Intuitive Surgical Com New (ISRG) | 1.5 | $47M | -35% | 83k | 566.36 |
|
| Thermo Fisher Scientific (TMO) | 1.5 | $47M | -29% | 81k | 579.45 |
|
| Brightspring Health Svcs (BTSG) | 1.4 | $45M | NEW | 1.2M | 37.45 |
|
| CVS Caremark Corporation (CVS) | 1.4 | $45M | +28% | 564k | 79.36 |
|
| Apogee Therapeutics (APGE) | 1.4 | $43M | -60% | 575k | 75.48 |
|
| Nurix Therapeutics (NRIX) | 1.3 | $41M | NEW | 2.2M | 18.97 |
|
| Vera Therapeutics Cl A (VERA) | 1.3 | $40M | +65% | 785k | 50.64 |
|
| Irhythm Technologies (IRTC) | 1.2 | $39M | -3% | 217k | 177.44 |
|
| Transmedics Group (TMDX) | 1.2 | $38M | -10% | 315k | 121.65 |
|
| BioMarin Pharmaceutical (BMRN) | 1.1 | $36M | +13% | 602k | 59.43 |
|
| Illumina (ILMN) | 1.1 | $35M | NEW | 270k | 131.16 |
|
| Kymera Therapeutics (KYMR) | 1.1 | $35M | +64% | 454k | 77.81 |
|
| Fulcrum Therapeutics (FULC) | 1.1 | $35M | +1294% | 3.1M | 11.31 |
|
| Penumbra (PEN) | 1.1 | $34M | -22% | 110k | 310.91 |
|
| Mbx Biosciences (MBX) | 1.0 | $32M | NEW | 1.0M | 31.54 |
|
| Rapt Therapeutics Com New (RAPT) | 1.0 | $32M | NEW | 930k | 33.87 |
|
| Caredx (CDNA) | 1.0 | $30M | -27% | 1.6M | 18.84 |
|
| Dyne Therapeutics (DYN) | 0.9 | $29M | -45% | 1.5M | 19.56 |
|
| Engene Holdings (ENGN) | 0.9 | $28M | +38% | 3.1M | 9.03 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.9 | $28M | -28% | 1.3M | 21.74 |
|
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 0.9 | $27M | 8.4M | 3.25 |
|
|
| Danaher Corporation (DHR) | 0.9 | $27M | -61% | 118k | 228.92 |
|
| Argenx Se Sponsored Adr (ARGX) | 0.8 | $26M | -59% | 31k | 840.95 |
|
| Natera (NTRA) | 0.8 | $26M | NEW | 112k | 229.09 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.8 | $25M | +6% | 324k | 78.04 |
|
| Terns Pharmaceuticals (TERN) | 0.7 | $23M | NEW | 575k | 40.40 |
|
| Evolus (EOLS) | 0.7 | $21M | NEW | 3.1M | 6.65 |
|
| Biogen Idec (BIIB) | 0.7 | $20M | NEW | 116k | 175.99 |
|
| Orthopediatrics Corp. (KIDS) | 0.6 | $20M | 1.1M | 17.76 |
|
|
| Tectonic Therapeutic (TECX) | 0.6 | $19M | +25% | 928k | 20.86 |
|
| Ventyx Biosciences (VTYX) | 0.6 | $17M | NEW | 1.9M | 9.03 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.5 | $17M | +28% | 3.2M | 5.24 |
|
| Compass Therapeutics (CMPX) | 0.5 | $15M | NEW | 2.8M | 5.37 |
|
| Monte Rosa Therapeutics (GLUE) | 0.5 | $15M | NEW | 948k | 15.68 |
|
| Harrow Health (HROW) | 0.5 | $15M | -13% | 295k | 49.00 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $14M | NEW | 3.4M | 4.00 |
|
| Repligen Corporation (RGEN) | 0.4 | $13M | -58% | 82k | 163.86 |
|
| Icon SHS (ICLR) | 0.4 | $13M | NEW | 73k | 182.22 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.4 | $13M | -51% | 314k | 41.25 |
|
| Grail (GRAL) | 0.4 | $12M | NEW | 143k | 85.59 |
|
| Surrozen Com New (SRZN) | 0.3 | $11M | +235% | 470k | 22.60 |
|
| Relmada Therapeutics (RLMD) | 0.2 | $7.6M | NEW | 1.6M | 4.83 |
|
| Xencor (XNCR) | 0.2 | $7.0M | -63% | 459k | 15.31 |
|
| Castle Biosciences (CSTL) | 0.2 | $6.9M | -78% | 177k | 38.90 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.2 | $5.1M | -57% | 312k | 16.24 |
|
| Billiontoone Cl A (BLLN) | 0.1 | $4.1M | NEW | 50k | 81.84 |
|
| Oruka Therapeutics (ORKA) | 0.1 | $2.6M | -93% | 85k | 30.31 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $2.2M | NEW | 303k | 7.36 |
|
| Pulmonx Corp (LUNG) | 0.1 | $1.7M | 753k | 2.21 |
|
Past Filings by Braidwell
SEC 13F filings are viewable for Braidwell going back to 2022
- Braidwell 2025 Q4 filed Feb. 17, 2026
- Braidwell 2025 Q3 filed Nov. 14, 2025
- Braidwell 2025 Q2 filed Aug. 14, 2025
- Braidwell 2025 Q1 filed May 15, 2025
- Braidwell 2024 Q4 filed Feb. 14, 2025
- Braidwell 2024 Q3 filed Nov. 14, 2024
- Braidwell 2024 Q2 filed Aug. 14, 2024
- Braidwell 2024 Q1 filed May 15, 2024
- Braidwell 2023 Q4 filed Feb. 14, 2024
- Braidwell 2023 Q3 filed Nov. 14, 2023
- Braidwell 2023 Q2 filed Aug. 14, 2023
- Braidwell 2023 Q1 filed May 15, 2023
- Braidwell 2022 Q4 filed Feb. 14, 2023